Vnitr Lek 2020, 66(4):E4 | DOI: 10.36290/vnl.2020.072

20 let klinických zkušeností s léčbou chronické myeloidní leukemie inhibitory tyrosinové kinázy

Edgar Faber
Hemato‑onkologická klinika LF UP a FN Olomouc

Published: June 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Faber E. 20 let klinických zkušeností s léčbou chronické myeloidní leukemie inhibitory tyrosinové kinázy. Vnitr Lek. 2020;66(4):E4. doi: 10.36290/vnl.2020.072.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Slezáková K, Mistrík M, Bátorová A. Súčasné možnosti liečby BCR‑ABL1 pozitívnej chronickej myelocytovej leukémie u dospelých pacientov. Vnitř Lek 2020; 66(4): 214-224.
    2. Talpaz M, Kantarjian H, Kurzrock R et al. Interferon‑alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome‑positive patients. Ann Intern Med 1991; 114: 532-538. Go to original source... Go to PubMed...
    3. Saussele S, Krauss MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 2015; 126: 42-49. Go to original source... Go to PubMed...
    4. Rea D, Lang F, Kim DW, et al. Asciminib, a Specific Allosteric BCR‑ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial. Blood 2018; 132: (Supl. 1): 792. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.